Targeting m<sup>6</sup>A RNA Modification in Tumor Therapeutics
The prevalent eukaryotic RNA modification N6-methyladenosine (m<sup>6</sup>A), which is distributed in more than 50% of cases, has demonstrated significant implications in both normal development and disease progression, particularly in the context of cancer. This review aims to discuss...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/159 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The prevalent eukaryotic RNA modification N6-methyladenosine (m<sup>6</sup>A), which is distributed in more than 50% of cases, has demonstrated significant implications in both normal development and disease progression, particularly in the context of cancer. This review aims to discuss the potential efficacy of targeting tumor cells through modulation of m<sup>6</sup>A RNA levels. Specifically, we discuss how the upregulation or downregulation of integral or specific targets is effective in treating different tumor types and patients. Additionally, we will cover the factors influencing the efficacy of m<sup>6</sup>A RNA targeting in tumor treatment. Our review will focus on the impact of targeting m<sup>6</sup>A mRNA on genes and cells and assess its potential as a therapeutic strategy for tumors. Despite the challenges involved, further research on m<sup>6</sup>A RNA in tumors and its integration with existing tumor therapy approaches is warranted. |
|---|---|
| ISSN: | 1198-0052 1718-7729 |